Spravato
If you have been looking for a new way to treat your depression, you may be interested in Spravato (esketamine) treatments. Harmony Bay is introducing Spravato to help control your depression symptoms.
Eskatamine, which is made from ketamine, is a groundbreaking treatment for depression that is giving people more hope than ever before.
For years, ketamine has been used as an anesthetic. However, it recently has made its way into the healthcare community to help treat depression, especially if your body does not respond well to standard antidepressants.
What is Spravato Treatment Program
In 2019, the FDA approved Spravato (esketamine) nasal spray to be administered by medical professionals to individuals with treatment-resistant depression.
This form of ketamine produces rapid and effective results and is well-suited for people with Major Depressive Disorder that haven’t had results after trying multiple types of antidepressant medications.
Under medical supervision, this nose spray for depression can be a game-changer for your depression when paired with an oral antidepressant.
Who Is Spravato Treatment Program for?
Spravato (Esketamine) is an FDA-approved prescription medication used along with an oral antidepressant for individuals with Treatment-Resistant Depression.
If you have been diagnosed with Major Depressive Disorder and have tried several antidepressant medications with poor results, Spravato may work for you.
Spravato By the Numbers
When delivered through a nose spray, Spravato takes on your depression by immediately impacting your brain cells, providing relief from depression. It can take anywhere from a couple of hours to a couple of days for you to start to notice a difference. However, ketamine treatments are still fast-acting and provide you with improved results quicker than your conventional antidepressants.
70% less likely
Spravato patients are 70% less likely to have a relapse of depressive symptoms.
24 hours
Improvement in depressive symptoms can be rapid, sometimes within 24 hours.
50% or greater
A study from Yale University found that 65% of their participants received a 50% or greater reduction in depressive symptoms by the end of treatment.
Up to 88%
Other trials have seen response rates up to 88%.
FAQs
